Fig 1: Bhlhe22 is expressed in differentiating granule cells in postnatal cerebellar development.(A) Bhlhe22 (green) and Neurod1 (red) immunofluorescent co-staining at P9.5 of taken from a posterior lobe IX. (B) Bhlhe22 (green) and NeuN (red) immunofluorescence co-staining at P6 taken from posterior lobe IX. (C) Bhlhe22 (red) and Dcx (green) immunofluorescent co-staining at P6 showing the posterior lobe IX; Labels: EGL = external granular layer IGL = internal granular layer, ML = molecular layer, Scalebars = 100 µm.
Fig 2: Upregulation of the neuronal marker TUBB3 by GW9662 treatment. (A) CHP212 cells were seeded in 12-well plates at a density of 5 × 103 cell/well, incubated overnight, and then exposed to 0 μM or 10 μM GW9662. Seven days after the treatment with GW9662, the cells were stained with an antibody directed against TUBB3 (green), and nuclei were stained with Hoechst 33342 (blue). The cells were examined using fluorescence microscopy (×40, bar: 20 μm). At the end of the experiment day, before immunostaining, microphotographs (×10) were taken using phase-contrast microscopy (B). (C) CHP212 cells were seeded in six-well plates at a density of 8 × 104 cells/well, incubated overnight, and treated with the indicated dose of GW9662 for 7 days. TUBB3, NFL, NeuroD1 were detected using western blot analysis. β-actin was loaded as an internal control.
Fig 3: Expression levels of pancreatic transcription factors at day 4. a Definitive endoderm (DE): FOXA2 (n = 5) and SOX17 (n = 6). b Primitive gut tube (PG): HNF1B (n = 5), posterior foregut endoderm: HNF6 (n = 6). c Pancreatic endoderm and endocrine precursor (PE): NGN3 (n = 6), PAX4 (n = 6), NKX2.2 (n = 6), and NEUROD1 (n = 6). Compared with ES, no transfection (=1) and transfection. *P < 0.05. N.S no significance. Error bars represent SEM (n = 5). d Immunofluorescence images of cells at day 3 for FOXA2, HNF1B, HNF4A, HNF6, and NEUROD1 all in green. Scale bars, 100 μm
Fig 4: In vivo conversion of striatal astrocytes into GABAergic neurons in WT mouse brain.a Coexpression of NeuroD1 (green) and Dlx2 (blue) together with mCherry (red, NeuroD1-p2A-mCherry and Dlx2-P2A-mCherry) in AAV-infected striatal astrocytes (GFAP, cyan) at 7 dpi. b At 30 dpi, NeuroD1 (green) and Dlx2 (blue) coexpressed cells became NeuN+ neurons (cyan). Scale bar for (a) and (b): 20 µm. c Summarized data showing coexpression of NeuroD1 and Dlx2 in striatal astrocytes at 7 dpi, which mostly converted into NeuN+ neurons by 30 dpi (n = 8 mice for 7 dpi, n = 9 mice for 30 dpi), data are shown as mean ± SEM. d Diagram illustrating the astrocyte-to-neuron conversion process induced by NeuroD1 and Dlx2 coexpression. e Representative images illustrating the gradual morphological change from astrocytes to neurons over a time window of 1 month. Note that most mCherry+ cells were co-labeled with GFAP (cyan) at early time points post AAV injection, but later lost GFAP signal and acquired NeuN signal (green). Arrowheads indicate mCherry+ cells that are co-labeled with NeuN. Scale bar: 50 µm. f Time course showing the cell identity (astrocyte vs neuron) among viral infected cells (mCherry+ cells) in the control group (mCherry+ alone, top graph, n = 5 for 7 dpi, n = 8 for 11 dpi, n = 9 for 15 dpi, n = 9 for 21 dpi, and n = 8 for 30 dpi) or NeuroD1 + Dlx2 group (bottom graph, n = 11 for 7 dpi, n = 8 for 11 dpi, n = 7 for 15 dpi, n = 6 for 21 dpi, and n = 10 for 30 dpi). Most of the viral infected cells in the control group were astrocytes, whereas the NeuroD1 + Dlx2-infected cells gradually shifted from mainly astrocytic population to a mixed population of astrocytes and neurons, and then to mostly neuronal population, data are shown as mean ± SD. g Confocal images showing converted neurons co-stained with GAD67, GABA, DARPP32, and parvalbumin (PV) after ectopic expression of NeuroD1 and Dlx2 in striatal astrocytes (30 dpi). Arrowheads indicate co-labeled cells. Scale bar: 20 µm. h Quantified data showing the composition of the astrocyte-converted neurons induced by NeuroD1 and Dlx2 in the striatum. Most of the converted neurons were GABAergic neurons (>80%) and a significant proportion were immunopositive for DARPP32 (55.7%), data are shown as mean ± SEM.
Fig 5: Generation of an LCSS for the ASCL1High and NEUROD1High NE-Lung cancer subtypes. a The volcano plot showing the indicated fold changes and P-values derived from t-test statistic. Proteins differentially present in the secretome between ASCL1High and NEUROD1High cells with an adjust P-value (FDR) < 0.05 are highlighted in pink and light blue, respectively. b The relative fold changes of the 65 significantly regulated secreted proteins in the secretome of 12 cell lines were grouped by unsupervised hierarchical clustering. c Transcriptomic clustering of 69 human SCLC tumors16 based on the AS/ND-LCSS gene expression markers (the pink bar indicates the AS-LCSS genes that are clustered with ASCL1, whereas the blue bar indicates the ND-LCSS genes that are clustered with NEUROD1). d–f Expression levels (FPKM) of ASCL1 (d), IGFBP5 (e), and B4GALT1 (f) in ASCL1High (n = 54) and ASCL1Low (n = 25) SCLC patient samples16. g–i Expression of ASCL1 (g), IGFBP5 (h), and B4GALT1 (i) in ASCL1High (n = 12) and ASCL1Low (n = 11) SCLC patient samples33. MAS5 intensity value averages of all probes for each gene in ASCL1High and ASCL1Low samples are indicated. Unpaired, two-tailed, Welch correction t-test results are indicated alongside the violin plots. The horizontal lines indicate the median and quartiles. Source data are provided as a Source Data file
Supplier Page from Abcam for Anti-NeuroD1 antibody [3H8] - BSA and Azide free